Cancer vaccines: on the threshold of success.
BACKGROUND
Cancer vaccines are a unique approach to cancer therapy. They exert an antitumor effect by engaging the host immune response, and have great potential for circumventing the intrinsic drug resistance that limits standard cancer management. Additional advantages of cancer vaccines are exquisite specificity, low toxicity, and the potential for a durable treatment effect due to immunologic memory.


OBJECTIVE
This review aims to consider the promise of cancer vaccines, review the current state of cancer vaccine development, and suggest directions for future research.


METHODS
The scope of this review was defined peer-reviewed information found on Medline, and information found on the Internet about Phase III clinical trials that are ongoing and not yet published.


CONCLUSIONS
Multiple Phase III clinical trials have demonstrated the promise and challenges posed by therapeutic vaccines, and defined the next steps in their clinical development. Determining the optimal integration of cancer vaccines with chemotherapy, radiation, surgery, and biologically targeted therapies, defining predictive biomarkers of immunologic and clinical response, and combining tumor vaccines with new drugs that effectively modulate the antitumor immune response, will ensure that cancer vaccines become part of standard cancer therapy and prevention.
Johns Hopkins University, Tumor Immunology and Breast Cancer Research Programs, Department of Oncology, 1650 Orleans Street, Room 409, Bunting Blaustein Cancer Research Building, Baltimore, MD 21231-1000, USA. emensle@jhmi.edu
Leisha A
LA
Emens
D000951:Antigens, Neoplasm / Q000276:immunology; D019496:Cancer Vaccines / Q000276:immunology / Q000627:therapeutic use*; D017326:Clinical Trials, Phase III as Topic; D003131:Combined Modality Therapy; D019008:Drug Resistance, Neoplasm; D006801:Humans; D009369:Neoplasms / Q000276:immunology / Q000517:prevention & control*
D000951:Antigens, Neoplasm; D019496:Cancer Vaccines